CMS’ current Medicare drug price negotiation guidance could negatively impact patient access to much-needed drugs and other forms of care, a key patient advocacy group told Inside Drug Pricing , echoing concerns from drug makers who stand ready to take legal action against CMS to stall implementation of the price negotiation process. Michael Ward, vice president of Public Policy and Government Relations for the Alliance for Aging Research, said CMS’ initial guidance published in March exacerbated the organization’s concerns that...